Choi Hye Ji Sally, Luong Christina, Fung Anthony, Tsang Teresa S M
Division of Cardiology and Cardiovascular Surgery, Vancouver General Hospital, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Diseases. 2018 Nov 16;6(4):104. doi: 10.3390/diseases6040104.
Coronary artery ectasia (CAE) is localized or diffuse dilatation of the coronary artery lumen exceeding the diameter of adjacent healthy reference segments by 1.5 times. It is a rare phenomenon and incidence ranges from 1 to 5% in patients undergoing angiography. We report a case of a 58-year-old man with atherosclerotic CAE who experienced ST-elevation myocardial infarction (STEMI) despite prophylactic antiplatelet therapy. He was successfully treated with IV eptifibatide and aspiration thrombectomy. We reviewed the literature of CAE presentation, etiology and treatment and discussed the most appropriate antithrombotic therapy to prevent STEMIs in patients with CAE. While the current literature appears to favour prophylactic antiplatelet and anticoagulant in these patients, more studies are needed to determine the optimal form and duration of antithrombotic therapy. Currently, there is no gold standard treatment for CAE and further prospective and randomized-controlled studies are needed to guide recommendations.
冠状动脉扩张(CAE)是指冠状动脉管腔局限性或弥漫性扩张,其直径超过相邻正常参考节段直径的1.5倍。这是一种罕见现象,在接受血管造影的患者中发生率为1%至5%。我们报告一例58岁患有动脉粥样硬化性CAE的男性患者,尽管接受了预防性抗血小板治疗,但仍发生了ST段抬高型心肌梗死(STEMI)。他通过静脉注射依替巴肽和血栓抽吸术成功治愈。我们回顾了有关CAE的表现、病因和治疗的文献,并讨论了预防CAE患者发生STEMI的最合适的抗栓治疗方法。虽然目前的文献似乎倾向于对这些患者进行预防性抗血小板和抗凝治疗,但仍需要更多研究来确定抗栓治疗的最佳形式和持续时间。目前,CAE尚无金标准治疗方法,需要进一步的前瞻性和随机对照研究来指导相关建议。